Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,460.00
+890.00 (11.76%)
Jun 29, 2026, 3:30 PM KST
Market Cap816.42B +53.7%
Revenue (ttm)3.13B -70.7%
Net Income-21.30B
EPS-221.60
Shares Out 96.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,083,989
Open7,570.00
Previous Close7,570.00
Day's Range7,570.00 - 8,480.00
52-Week Range4,395.00 - 21,500.00
Beta0.82
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2025, Hyundai Bioscience's revenue was 3.52 billion, a decrease of -76.63% compared to the previous year's 15.05 billion. Losses were -22.13 billion, 219.3% more than in 2024.

Financial Statements